CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Key facts
- Who runs it
- Universitätsklinikum Hamburg-Eppendorf
- Where
- Boston, Houston, Los Angeles, Minneapolis, Morristown, New York, Oklahoma City, Tampa, and Tucson, United StatesSee the 9 sitesAlso in 12 other countries, 34 sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Nov 2020
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 4 groups
- Record updated
- 7 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- clinically significant mitral insufficiency
- patient underwent screening for TMVI
- echocardiography data at baseline (and after TMVI, E2E and surgery)
- follow-up of at least 30 days
Who cannot take part
- age under 18 years
Where in United States
Also in 12 other countries, 34 sites
- Brigham and Women's HospitalBoston, United StatesContact: Tsuyoshi Kaneko, MDTaking people
- Houston Methodist HospitalHouston, United StatesContact: Michael Reardon, MDTaking people
- Cedars-Sinai Medical Center_Los AngelesLos Angeles, United StatesContact: Raj Makkar, MDTaking people
- Minneapolis Heart Institute at Abbott Northwestern HospitalMinneapolis, United StatesContact: Paul Sorajja, MDTaking people
- Morristown Medical CenterMorristown, United StatesContact: Philippe Généreux, MDTaking people
- Montefiore Medical CenterNew York, United StatesContact: Azeem Latib, MDTaking people
- Oklahoma Heart HospitalOklahoma City, United StatesContact: Naeem Tahirkheli, MDTaking people
- Tampa General HospitalTampa, United StatesContact: Hiram G. Bezerra, MDTaking people
- Tucson Medical CenterTucson, United StatesContact: Thomas E. WaggonerTaking people
About the trial
What the trial wants to find out
This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice.
Read full original descriptionShow less
Patients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical/conservative therapy.
The 4 groups in the trial
- Transcatheter Mitral Valve Replacement (TMVR)
Patients with successful TMVR screening, who underwent Transcatheter Mitral Valve Replacement subsequently. All devices may be included.
- Mitral transcatheter edge-to-edge repair (M-TEER)
Patients with TMVR screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair. Update: These patients are currently no longer systematically included.
- Mitral valve surgery (Surgery)
Patients with TMVR screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement). Update: These patients are currently no longer systematically included.
- Medical/conservative therapy
Patients with TMVR screening failure, who subsequently underwent conservative or optimal medical therapy. Update: These patients are currently no longer systematically included.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry
- Publications
- Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement: Results From the CHOICE-MI Registry.JACC. Cardiovascular interventions, 2026
- Phenotypic clustering analysis of patients rejected for mitral valve interventions: implications for future transcatheter technologies.European heart journal. Cardiovascular Imaging, 2025
- Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification.JACC. Cardiovascular interventions, 2024
- Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison.Circulation. Cardiovascular interventions, 2023
- Record updated
- 7 May 2026